Publications

1. Dr. Ambrish Mithal ( CHAIRMAN, HOD, Division of Endocrinology and Diabetes )
2. Dr. Nikhil Tandon ( Professor & Head – Department of endocrinology, metabolism and diabetes )
3. Dr. Sanjay Kumar Bhadada ( Postgraduate Institute of Medical Education and Research (PGIMER) )
4. Dr. Manoj Chadha – P. D. Hinduja Hospital and Medical Research Centre
5. Dr. Ritu Trivedi, PhD, FNASC

Key publications on Bone

1. Calcium repletion to rats with calcipenic rickets fails to recover bone quality
2. Parveen B, Parveen A, Vohora D. Biomarkers of Osteoporosis: An Update.EndocrMetab Immune Disord Drug Targets. 2019 Feb 4.
3. Kumar M, Jiloha RC, Kataria D, Prasad S, Vohora D. Effect of selective serotonin reuptake inhibitors on markers of bone loss.Psychiatry Research 2019 Jun;276:39-44.
4. Wadhwa R, Kumar M, Paudel YN, Iqbal R, Kothari P, Trivedi R, Vohora D. Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study.Journal of Bone Mineral Metabolism 2019 Jan;37(1):36-42
5. Parveen B, Tiwari AK, Jain M, Pal S, Chattopadhyay N, Tripathi M, Vohora D. The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats. BONE 2018 Aug; 113: 57-67
6. Kumar M, Wadhwa R, Kothari P, Trivedi R, Vohora D. Differential effects of serotonin reuptake inhibitors fluoxetine and escitalopram on bone markers and microarchitecture in Wistar rats.European Journal of Pharmacology 2018 Apr 15;825:57-62
7. Parveen B, Tripathi M, Vohora D. A Cross-Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti-Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor κ B Ligand in Indian Women with Epilepsy.Basic Clin PharmacolToxicol. 2018 Sep;123(3):271-276.
8. Vohora D, Parveen B. Tartarate resistant acid phosphatase as a biomarker of bone remodeling. In: Preedy VR (Ed) Biomarker in Bone Disease e, Biomarkers in Disease: Methods, Discoveries and Applications, DOI 10.1007/978-94-007-7745-3_42-1, Springer Science+Business Media Dordrecht 2017.
9. Wadhwa R, Yadav MK,Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporosis and Sarcopenia 2017; 3: 75-81.
10. Kalam A, Talegaonkar S, Vohora D. Effects of raloxifene against letrozole-induced bone loss in chemically induced model of menopause in mice. Mol. Cell. Endocrinol. 2017; 440: 34-43
11. Kalam A, Talegaonkar S, Vohora D. Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexenediepoxide treated ovotoxic female mice.FundamClinPharmacol. 2016; 30: 429-439
12. Anwar MJ, Radhakrishna KV, Sharma A, Vohora D. Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice. European J Pharm Sci. 2014; 62: 219-226
13. Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induces bony alterations in female mice. Canadian J Physiol. Pharmacol. 2014; 92: 507-511
14. Khanna S, Pillai KK, Vohora D. Bisphosphonates in phenytoin-induced bone disorder. BONE2011 (Mar); 48: 597-606
15. Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discovery Today 2009; 14: 428-434

Articles

1. Modern india and the tale of twin nutrient deficiency-calcium aqnd vitamin D-nutrition trend data 50 years-retrospect and prospect, by Chittari V Harinarayan, H AKHILA
2. Clinical Focus Series: Bone and Mineral Disorders
3. An article on “Oral dosing of pentoxifylline”
   by Dr. Naibedya Chattopadhyay